

King Saud University

Saudi Pharmaceutical Journal

www.ksu.edu.sa www.sciencedirect.com



REVIEW

Low density lipoprotein bionanoparticles: From cholesterol transport to delivery of anti-cancer drugs



Gamaleldin I. Harisa a,b,*, Fars K. Alanazi a

Received 29 September 2013; accepted 14 December 2013 Available online 22 December 2013

KEYWORDS

Nanoparticles; Biological nanoparticles; LDL; LDL receptor; Drug delivery; Cancer **Abstract** In this review article, we highlight the importance of low-density lipoprotein (LDL) and its implications in the field of drug delivery to cancer cells. LDL is naturally occurring bionanoparticles (BNP) with a size of 18–25 nm. These BNPs specifically transport cholesterol to cells expressing the LDL receptors (LDLRs). Several tumors overexpress LDLRs, presumably to provide cholesterol for sustaining a high rate of membrane synthesis. LDL BNPs are biocompatible and biodegradable, favorably bind hydrophobic and amphiphilic drugs, are taken up by a receptor-mediated mechanism, have a half-life of 2–4 days, and can be rerouted. Drugs can be loaded onto LDL BNPs by surface loading, core loading, and apoprotein interaction. LDL may be used as a drug carrier for treatment of atherosclerosis, cancer, and in photodynamic therapies.

© 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).

Contents

1.	Introduction	505
2.	Lipoproteins as natural drug delivery systems	506
	2.1. Lipoproteins as bionanoparticles (BNPs)	507
3.	LDL as a bionanoparticle	507
	3.1 The LDL recentors	508

^{*} Corresponding author at: Department of Pharmaceutics, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia. Tel.: +966 546269544; fax: +966 (1)4676295. E-mail address: gamal.harisa@yahoo.com (G.I. Harisa). Peer review under responsibility of King Saud University.



Production and hosting by Elsevier

^a Kayyali Chair for Pharmaceutical Industry, Department of Pharmaceutics, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia

^b Department of Biochemistry, College of Pharmacy, Al-Azhar University (Boys), Nasr City, Cairo, Egypt

	3.2.	Role of apolipoprotein B-100 in LDLR binding	509
	3.3.	LDL and cell growth	510
	3.4.	The LDLRs in cancer cells	510
	3.5.	Sources of LDL	511
	3.6.	Advantages of LDL BNPs as drug carriers	511
	3.7.	Disadvantages of LDL BNPs as a drug carrier	511
	3.8.	Methods of loading drugs into LDL particles	511
	3.8	.1. Surface loading	512
	3.8	.2. Core loading	512
	3.8	.3. Apoprotein loading	512
4.	LDI	as a drug carrier	512
	4.1.	LDL as a drug carrier for atherosclerosis treatment	512
	4.2.	LDL as a drug carrier for anticancer drugs	513
	4.3.	LDL as a drug carrier for anticancer photodynamic therapy	513
5.	Con	clusions	513
	Confl	ict of interest	513
	Ack	nowledgements	513
	Refere	ences	514

1. Introduction

Nanoparticulate matter is a collection of particles with at least one dimension that is smaller than 1 μ m but larger than atoms and molecules. The size of nanomaterials is similar to that of most biological molecules and structures (Buzea et al., 2007). Fig. 1 represents definition of nano and micro sizes and some biological nanomaterials.

The therapeutic or diagnostic agents of interest are encapsulated within nanoparticles using a polymeric matrix and are adsorbed or conjugated onto the nanoparticle surface (Misra et al., 2010). Nanoparticles may be targeted to specific sites via the receptors on target cells that elicit specific

biochemical interactions (Misra et al., 2010). The universal structural topology of nanoparticles consists of a core compartment with terminal surface groups (Misra et al., 2010). Nanosized materials (5–100 nm) are used in various applications. The use of therapeutic nanoparticles as unique drug delivery systems will soon be a significant addition to current cancer therapeutics. This technology has enabled the manipulation of the biological and physicochemical properties of materials to facilitate more efficient drug targeting and delivery (Buzea et al., 2007).

Bionanotechnology, a subdivision of nanotechnology focuses on the development of novel nanoscalematerials from biological building blocks (Lee and Wang, 2006). Natural




Figure 1 Represents size of nanomaterials compared to biological components and definition of nano and micro sizes.

Download English Version:

https://daneshyari.com/en/article/2509531

Download Persian Version:

https://daneshyari.com/article/2509531

<u>Daneshyari.com</u>